Skip to content
Open access

A deep-learning model based on histological images predicts survival and pathological response to neoadjuvant chemotherapy and chemoimmunotherapy in breast cancer

Nov 2026 · Journal of Translational Medicine · 0 citations

TL;DR

An artificial intelligence (AI)-based deep-learning model enables accurate inference of a clinically validated immune gene-expression program directly from routine H&E slides and is independently associated with survival and pCR to NACT/NACTIT in eBC.

Abstract

Accurate biomarkers for prognosis and selection of patients most likely to benefit from neoadjuvant chemoimmunotherapy in early breast cancer (eBC) are urgently needed. The Immune Constant of Rejection (ICR) gene expression signature, a 20-gene signature reflecting cytotoxic immune activation, is associated with favorable prognosis and pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in eBC. However, ICR requires transcriptomic profiling, restricting its routine clinical implementation. We hypothesized that the biological features captured by ICR could be inferred directly from routine hematoxylin-eosin (H&E) whole-slide images (WSIs) using deep learning. We developed an artificial intelligence (AI)-based deep-learning model to predict ICR class (AI-ICR model) from WSIs and tested its predictive value for survival and pCR to NACT and neoadjuvant chemoimmunotherapy (NACTIT). Our model was trained using WSIs from 2,881 TCGA non-BC multicancer samples paired with RNA-sequencing-derived ICR classification. It was externally validated in 1,087 TCGA BC samples and 104 pretreatment biopsies from two BC prospective neoadjuvant trials. We assessed its association with overall survival (OS) in TCGA and with pCR to NACT/NACTIT in the neoadjuvant cohorts (PELICAN+NEO-R-IPC). AI-ICR model showed a 0.917 average cross-validated AUC in the mutlicancer internal test set, and performed well in external eBC series, with 0.937 AUC in TCGA ( p  = 4·13E-45) and 0.739 in PELICAN+NEO-R-IPC ( p  = 5·00E-03), thus demonstrating robustness across tumor types, tissue preparations, and acquisition platforms. AI-ICR-high tumors displayed longer OS than AI-ICR-low tumors with Hazards-Ratio for death of 0.29 [95%CI 0.15–0.55] in multivariate analysis ( p  = 1·69E-04). They also displayed larger pCR rate than AI-ICR-low tumors, with an Odds-Ratio for pCR of 4.33 [95%CI 1.68–11.2] in multivariate analysis ( p  = 2·47E-03), and this difference was stronger in the NACTIT arm (81% versus 36%) than in the NACT arm (65% versus 30%). Transcriptomics showed enrichment of immune genes and activated immune cell types in AI-ICR-high tumors. AI-ICR enables accurate inference of a clinically validated immune gene-expression program directly from routine H&E slides and is independently associated with survival and pCR to NACT/NACTIT in eBC. After further validation of both ICR inference and clinical outcome prediction in larger series, it could represent a simple, inexpensive and scalable alternative to transcriptomic profiling for precision management of eBC, including routine AI-assisted immuno-oncology.

Read PDF

Similar papers

Open access Oct 2026

Machine learning model for the prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer

Breast cancer patients receiving neoadjuvant treatment may benefit from a presurgical assessment of complete response to avoid unnecessary surgeries. We aimed to develop a machine learning model that predicts pathological complete response (pCR) based on results from different image modalities as well as tumor and pati...

Eva Reisig, Lie Cai, Maria Müller et al. · 0 citations
Open access Oct 2026

Development and validation of a deep learning model integrating 18F-FDG PET/CT radiomics and clinical features to predict major pathological response in non-small cell lung cancer patients receiving chemoimmunotherapy

Background Pathological complete response (pCR) and major pathological response (MPR) are early measures of treatment efficacy with prognostic relevance in patients with non-small cell lung cancer (NSCLC) receiving neoadjuvant chemoimmunotherapy. Individual biomarkers such as programmed cell death-ligand 1 (PD-L1) and...

Ao Li, Zi-Hao Mao, Hai-Long Wang et al. · 0 citations
Oct 2026

A deep learning radiomics model based on multiparametric MRI for predicting the efficacy of neoadjuvant chemotherapy in axillary lymph nodes of breast cancer.

OBJECTIVES In this study, we developed and validated a deep learning radiomics clinical (DLRC) model integrating multiparametric MRI (mpMRI) and clinical data to predict axillary pathological complete response (apCR) in cN+ breast cancer patients receiving neoadjuvant chemotherapy (NAC). MATERIALS AND METHODS We retr...

Meng-Ling Liu, Ran Li, Ai-Ling Chen et al. · 0 citations
Open access Sep 2026

A cfDNA fragmentomics-based machine learning model for predicting treatment response and recurrence in locally advanced rectal cancer after neoadjuvant chemoradiotherapy

Neoadjuvant chemoradiotherapy (nCRT) is standard treatment for locally advanced rectal cancer (LARC), but responses vary substantially. We developed Fragmentia-AI Response, a machine learning model that uses cell-free DNA (cfDNA) fragment features to predict pathological response and recurrence risk without relying on...

Kun Miao, S. Wang, Guo-Feng Sun et al. · 0 citations
Open access Sep 2026

Prediction of pathological complete response to neoadjuvant chemo-immunotherapy in locally advanced lung adenocarcinoma: a multimodal machine learning approach

Predicting pathological complete response (pCR) following neoadjuvant chemo-immunotherapy in locally advanced lung adenocarcinoma (LUAD) remains clinically challenging. We aimed to develop an explainable machine learning framework to predict pCR and stratify patient prognosis. This retrospective study included 627 driv...

Bin Liu, Yan-Yan Fu, Yuan-Jin Ma · 0 citations
#artificial intelligence Review Oct 2026

Transcriptome-informed multi-modal AI for predicting neoadjuvant therapy response from breast cancer biopsies

A two-stage AI model predicting pathological complete response to neoadjuvant therapy in breast cancer and transcriptome-wide inference improves discrimination over clinical variables alone or one-stage pathology models, and robustness by avoiding genomic assays'gene selection constraints are developed.

Jungkyu Park, D. Biswas, J. Cappadona et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.